Richard Law
Stock Analyst at Goldman Sachs
(0.12)
# 4,376
Out of 5,041 analysts
67
Total ratings
25%
Success rate
-30.57%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Richard Law
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRNX Crinetics Pharmaceuticals | Maintains: Neutral | $35 → $40 | $40.99 | -2.42% | 1 | Sep 26, 2025 | |
| MLYS Mineralys Therapeutics | Maintains: Buy | $32 → $52 | $39.90 | +30.33% | 7 | Sep 9, 2025 | |
| VRDN Viridian Therapeutics | Maintains: Buy | $27 → $30 | $22.16 | +35.38% | 4 | Aug 7, 2025 | |
| MLTX MoonLake Immunotherapeutics | Maintains: Buy | $74 → $82 | $9.52 | +761.34% | 4 | Aug 6, 2025 | |
| ARQT Arcutis Biotherapeutics | Initiates: Neutral | $18 | $20.11 | -10.49% | 1 | Jul 25, 2025 | |
| OLMA Olema Pharmaceuticals | Maintains: Buy | $20 → $18 | $8.03 | +124.16% | 5 | May 14, 2025 | |
| SLN Silence Therapeutics | Maintains: Sell | $4 → $3 | $7.30 | -58.90% | 3 | May 9, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Neutral | $15 → $13 | $3.85 | +237.66% | 3 | May 9, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Neutral | $36 → $31 | $26.72 | +16.02% | 3 | May 9, 2025 | |
| VKTX Viking Therapeutics | Initiates: Neutral | $30 | $34.42 | -12.84% | 1 | Apr 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $73 | $94.88 | -23.06% | 1 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $11 | $11.14 | -1.26% | 4 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $46 → $47 | $27.96 | +68.10% | 3 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $62 → $63 | $67.61 | -6.82% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $36 → $37 | $58.56 | -36.82% | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $76 | $25.60 | +196.88% | 6 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $14 | $3.72 | +276.34% | 3 | May 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $61 | $9.21 | +562.32% | 4 | May 8, 2023 |
Crinetics Pharmaceuticals
Sep 26, 2025
Maintains: Neutral
Price Target: $35 → $40
Current: $40.99
Upside: -2.42%
Mineralys Therapeutics
Sep 9, 2025
Maintains: Buy
Price Target: $32 → $52
Current: $39.90
Upside: +30.33%
Viridian Therapeutics
Aug 7, 2025
Maintains: Buy
Price Target: $27 → $30
Current: $22.16
Upside: +35.38%
MoonLake Immunotherapeutics
Aug 6, 2025
Maintains: Buy
Price Target: $74 → $82
Current: $9.52
Upside: +761.34%
Arcutis Biotherapeutics
Jul 25, 2025
Initiates: Neutral
Price Target: $18
Current: $20.11
Upside: -10.49%
Olema Pharmaceuticals
May 14, 2025
Maintains: Buy
Price Target: $20 → $18
Current: $8.03
Upside: +124.16%
Silence Therapeutics
May 9, 2025
Maintains: Sell
Price Target: $4 → $3
Current: $7.30
Upside: -58.90%
Rocket Pharmaceuticals
May 9, 2025
Maintains: Neutral
Price Target: $15 → $13
Current: $3.85
Upside: +237.66%
Celldex Therapeutics
May 9, 2025
Maintains: Neutral
Price Target: $36 → $31
Current: $26.72
Upside: +16.02%
Viking Therapeutics
Apr 8, 2025
Initiates: Neutral
Price Target: $30
Current: $34.42
Upside: -12.84%
Nov 21, 2024
Initiates: Buy
Price Target: $73
Current: $94.88
Upside: -23.06%
Aug 11, 2023
Reiterates: Neutral
Price Target: $11
Current: $11.14
Upside: -1.26%
Aug 9, 2023
Maintains: Neutral
Price Target: $46 → $47
Current: $27.96
Upside: +68.10%
Aug 8, 2023
Maintains: Neutral
Price Target: $62 → $63
Current: $67.61
Upside: -6.82%
Aug 4, 2023
Maintains: Neutral
Price Target: $36 → $37
Current: $58.56
Upside: -36.82%
Jun 13, 2023
Reiterates: Outperform
Price Target: $76
Current: $25.60
Upside: +196.88%
May 8, 2023
Maintains: Neutral
Price Target: $15 → $14
Current: $3.72
Upside: +276.34%
May 8, 2023
Reiterates: Outperform
Price Target: $61
Current: $9.21
Upside: +562.32%